ClinicalTrials.gg
Active, not recruitingNCT07187297Updated Nov 6, 2026

A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment

An interventional study of Thermage FLX in Wrinkle, Lax Skin and Lines Skin, sponsored by Bausch Health Americas, Inc.. Active, not recruiting at 6 sites in United States. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Prevention

How we know

Updated Nov 6, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Study summary

A prospective, 180-day, randomized, multicenter, independent blinded evaluators, controlled study of treatment with the Thermage FLX System

Read the detailed description

Study to be conducted at approximately 10 study centers, enrolling a total of 164 participants in North America (US and Canada) and China. Approximately 6 months (26 weeks) Purpose is to demonstrate superiority of treatment with the Thermage FLX System compared to untreated control for the improvement of:

Lines and wrinkles of the neck and face Skin laxity of the neck, abdomen, upper arms, and face and evaluate safety and tolerability of treatment with the Thermage FLX System compared to the untreated control arm.

02

Conditions studied

  • Wrinkle
  • Lax Skin
  • Lines Skin
03

In context

Lead sponsor

Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 19 (73%) have results posted.

First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be an adult female or male, ≥30 - ≤60 years of age.

Have mild-to-moderate skin laxity of the neck, abdomen, upper arms, and/or face, and/or mild-to-moderate lines and/or wrinkles of the neck and/or face assessed as follows:

Neck:

Mild-to-moderate neck skin laxity as defined by a score of 1 to 6 on the 10-point Facial Laxity Rating Scale (scored 0-9)

Mild-to-moderate neck wrinkles as defined by a score of 1 to 6 on the 10-point Fitzpatrick Wrinkle Scale (scored 0-9)

Abdomen:

Mild-to-moderate abdomen skin laxity as defined by a score of 1 or 2 on a 4-point Abdominal Laxity Scale (scored 0-3)

Upper arms:

Mild to moderate upper arms skin laxity as defined by grade 2 or 3 on the 5-grade IBSA Inner Upper Arm Laxity Scale

Face:

Mild-to-moderate facial skin laxity as defined by a score of 1 to 6 on the 10-point Facial Laxity Rating Scale (scored 0-9)

Mild-to-moderate facial wrinkles as defined by a score of 1 to 6 on the 10-point Fitzpatrick Wrinkle Scale (scored 0-9)

Females of must have a negative urine pregnancy test. Females who have experienced menarche and who are not (either confirmed via FSH testing or who have not menstruated for 2 years or more without an alternative medical cause) or surgically sterile will be considered of childbearing potential.

Females of childbearing potential must agree to use an acceptable method of for the duration of the study. Acceptable methods of birth control are oral and other systemic contraceptives, condoms only, intrauterine device, double-barrier methods, bilateral tubal ligation, partner vasectomy, and abstinence.

Have no clinically abnormal findings based on the medical history as determined by the study investigator.

Be able to follow the study instructions, be available on the specific required study visit days, and be willing to complete all study visit procedures and assessments.

Understand the research nature of this study and sign an document prior to the performance of any study-specific procedure or assessment.

Agree to not undergo excluded procedures (i.e., energy-based device treatments, injectables, or plastic surgery) on the study treatment areas for the duration of study.

Participant has a (BMI) ≤30.

Exclusion criteria

Exclusion Criteria:

  • Participant is pregnant or breast feeding or trying to become pregnant for 3 months prior to the screening visit or during the study.

Participant has given birth within 3 months prior to the screening visit.

Participant has an anticipated need for procedures, surgery, overnight hospitalization, or other events that would prevent the participant from making the required visits during the study.

Participant has a pacemaker, internal defibrillator, or other implanted electronic device.

Participant has an implant in the target treatment zone(s).

Participant has had radiation therapy in the target treatment zone(s).

Participant has had 1 or more prior cosmetic procedures in the target treatment zone(s) including:

Thermage or any energy-based device procedure, derm abrasion, or chemical peel on any treatment area within 6 months prior to the screening visit.

Short-acting neurotoxins within 6 months prior to the screening visit.

Long-acting neurotoxins within 9 months prior to the screening visit.

Hyaluronic acid filler ≤1 year prior to the screening visit.

Semi-permanent or permanent fillers at any time prior to the screening visit.

Plastic surgery within 1 year prior to the screening visit.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
164 participants (estimated)

Study arms

  • Active comparator
    Control Arm

    Treated with Thermage FLX device at day 90

    Device: Thermage FLX

  • Experimental
    Treatment Arm

    Treated with Thermage FLX device at day 1

    Device: Thermage FLX

Interventions

  • DeviceThermage FLX

    The Thermage FLX System ('System') is a monopolar, capacitively coupled radiofrequency System designed for use in non-invasive dermatological procedures

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    Proportion of participants with any improvement on iGAIS at Day 90 as assessed by independent blinded evaluators.

    Time frame: 90 days

Secondary outcomes

  1. Secondary Endpoint

    Proportion of participants with any improvement on iGAIS, Fitzpatrick Wrinkle Scale, Facial Laxity Rating Scale, IBSA Inner Upper Arm Laxity Scale, Abdominal Laxity Scale at Day 90 and 180.

    Time frame: 180 days

07

Study locations

6 sites
  • Laser & Skin Surgery Center of Northern California
    Sacramento, California 95816, United States
  • Cosmetic Laser Dermatology
    San Diego, California 92121, United States
  • Chicago Cosmetic Surgery and Dermatology
    Chicago, Illinois 60654, United States
  • SkinCare Physicians
    Chestnut Hill, Massachusetts 02467, United States
  • Union Square Laser Dermatology
    New York, New York 10003, United States
  • Dermatology and Laser Surgery Center
    Houston, Texas 77004, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Oct 2026, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Feb 2027 → Oct 2026 and completion Mar 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Sep 22, 2025
StartActual
Oct 31, 2025
Primary completionActual
Oct 22, 2026was Feb 2027
CompletionEst.
Sep 2027was Mar 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 6, 2026
Sites
1 site removed
Show 1 removed
  • Cosmetic Laser Dermatology · San Diego, United States
Nov 6, 2026
Primary completion
Feb 2027→Oct 22, 2026 (actual)
Nov 6, 2026
Study completion
Mar 2027→Sep 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • Cosmetic Laser Dermatology · San Diego, United States
    Primary completion Feb 2027→Oct 22, 2026 (now actual)
    Study completion Mar 2027→Sep 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07187297
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Oct 31, 2025
Primary completion
Oct 22, 2026
Completion
Sep 2027 (estimated)
Last update
Nov 6, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion